Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Gene-based products company expands AAV patent portfolio
August 6th, 2004
Targeted Genetics Corporation (TGEN) announced the issuance of a patent for its AAV (adeno-associated viral) vector technology. The company utilizes AAV vectors to deliver genes into targeted cells to treat or prevent disease. The new patent, entitled "Adeno-Associated Virus Serotype 1 Nucleic Acid Sequences, Vectors and Host Cells Containing Same," covers AAV vectors with sequences from AAV serotype 1. It was issued to the University of Pennsylvania and is exclusively licensed to Targeted Genetics. "Studies by a number of groups have demonstrated that AAV vectors containing AAV1 serotype capsids are extremely efficient for gene expression when...
Source: Genomics & Genetics Weekly (2004-08-06)
|
